Gene therapy was first conceptualized in 1972 with the resources promise to correct numerous inheritable diseases. Further study will reveal the clinical promise of NIS gene therapy in the treatment of prostate as well as other malignancies. Preclinical successes resources have culminated in the opening of a phase I trial for patients with advanced prostate disease which is currently accruing patients. Studies have demonstrated that transfer of the human NIS gene into prostate cancer using adenovirus vectors in vitro and in vivo results in efficient uptake of radioactive iodine and significant tumor growth delay with prolongation of survival.
Published results from Mayo Clinic researchers have indicated several important successes with the use of the NIS gene and prostate gene therapy. The characteristics of resources the NIS gene suggest that it could represent an ideal therapeutic gene for cancer therapy. The sodium-iodide symporter (NIS) is responsible for the ability of the thyroid gland to transport and concentrate iodide. The approach resources utilizing gene therapy in prostate cancer patients at our institution attempts to address this deficiency.